TABLE 1.

In vitro and in vivo activities of RWJ-416457, linezolid, and vancomycin against gram-positive pathogens in mouse lethal infection models

Model and strain (type)CompoundMIC (μg/ml)ED50, mg/kg/day (95% fiducial limit)
p.o.s.c.i.v.
S. aureus systemic infection models
    ATCC 13709 (MSSA)RWJ-41645713.4 (2.7-4.5)4.7 (3.2-6.8)4.0 (3.0-5.2)
Linezolid26.4 (5.2-7.8)7.0 (5.4-9.1)6.3 (4.2-9.8)
Vancomycin1NAa1.7 (0.9-2.9)0.9 (0.6-1.4)
    OC8525 (CA-MRSA)RWJ-41645722.1 (1.3-3.0)3.5 (2.5-4.5)1.5 (0.6-2.3)
Linezolid45.1 (2.7-7.8)3.7 (1.7-5.7)8.5 (6.5-11)
Vancomycin1NA12 (10-14)5.6 (3.7-11)
S. pneumoniae lung infection model
    ATCC 6301 (PSSP)RWJ-41645713.1 (2.0-4.9)9.3 (5.6-31)18 (13-26)
Linezolid214 (9.5-28)20 (13-26)>40
  • a NA, not applicable.